Cost of Patients with Primary Open-angle Glaucoma. A Retrospective Study of Commercial Insurance Claims Data

Ophthalmology

Volumn 114, Issue 7, 2007, Pages 1241-1247

  Lee, Paul P ^a   Levin, Leonard A ^b   Walt, John G ^c   Chiang, Tina ^c   Katz, Laura M ^d   Dolgitser, Margarita ^d   Doyle, John J ^d   Stern, Lee S ^d  

^a DUKE UNIVERSITY EYE CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c ALLERGAN INC   (United States)

^d Analytical International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; EYE CARE; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PATIENT SELECTION; PHARMACY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; UNITED STATES;

AGED; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH; LINEAR MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 34347271915     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2006.10.031     Document Type: Article

References (25)

1. Eye Diseases Prevalence Research Group. Arch Ophthalmol 122 (2004) 532-538
2. American Academy of Ophthalmology Glaucoma Panel. Preferred practice pattern. Primary open-angle glaucoma 6 (2005), American Academy of Ophthalmology, San Francisco. http://www.aao.org/education/library/ppp/upload/Primary_Open-Angle_Glaucoma.pdf Available at: http://www.aao.org/education/library/ppp/upload/Primary_Open-Angle_Glaucoma.pdf. Accessed October 9, 2006
3. Quigley H.A., and Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 38 (1997) 83-91
4. Tielsch J.M., Sommer A., Katz J., et al. Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye Survey. JAMA 266 (1991) 369-374
5. Chen P.P. Risk and risk factors for blindness from glaucoma. Curr Opin Ophthalmol 15 (2004) 107-111
6. Distelhorst J.S., and Hughes G.M. Open-angle glaucoma. Am Fam Physician 67 (2003) 1937-1944
7. Glick H., Brainsky A., McDonald R.C., and Javitt J.C. The cost of glaucoma in the United States in 1988. Chibret Int J Ophthalmol 10 (1994) 6-12
8. Rein D.B., Zhang P.H., Wirth K.E., et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 124 (2006) 1754-1760
9. Kobelt G. Health economics, economic evaluation, and glaucoma. J Glaucoma 11 (2002) 531-539
10. Kobelt-Nguyen G., Gerdtham U.G., and Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 7 (1998) 95-104
11. Lee P.P., Walt J.G., Doyle J.J., et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 124 (2006) 12-19
12. Oostenbrink J.B., Rutten-van Molken M.P., and Sluyter-Opdenoordt T.S. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma 10 (2001) 184-191
13. Iskedjian M., Walker J., Vicente C., et al. Cost of glaucoma in Canada: analyses based on visual field and physician's assessment. J Glaucoma 12 (2003) 456-462
14. Vold S.D., Riggs W.L., and Jackimiec J. Cost analysis of glaucoma medications: a 3-year review. J Glaucoma 11 (2002) 354-358
15. Fiscella R.G. Costs of glaucoma medications. Am J Health Syst Pharm 55 (1998) 272-275
16. Stewart W.C., Hudgins A.C., Pruitt C.A., and Sine C. Daily cost of newer glaucoma agents. J Ocul Pharmacol Ther 15 (1999) 379-388
17. Ollendorf D.A., Massarotti E., Birbara C., and Burgess S.M. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 11 (2005) 383-393
18. Gilbert Jr. T.D., Smith D., and Ollendorf D.A. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 5 (2004) 36
19. Joyce A.T., Iacoviello J.M., Nag S., et al. End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care 27 (2004) 2829-2835
20. Ollendorf D.A., Joyce A.T., and Rucker M. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. MedGenMed [serial online] 6 (2004) 5. http://www.medscape.com/viewarticle/466800 Available at: http://www.medscape.com/viewarticle/466800. Accessed May 30, 2006
21. U.S. Department of Labor Bureau of Labor Statistics. Consumer price index-all urban consumers. U.S. Medical Care Services, 1982-84=100 - CUUR0000SAM2. Available at: http://data.bls.gov/cgi-bin/surveymost?cu. Accessed May 30, 2006.
22. Dang D.K., Pont J.M., and Portmoy M.A. Episode treatment groups: an illness classification and episode building system-part II. Med Interface 9 (1996) 122-128
23. Coleman A.L., and Morgenstern H. Use of insurance claims databases to evaluate the outcomes of ophthalmic surgery. Surv Ophthalmol 42 (1997) 271-278
24. Keister L.W. Managed care's "revolving door". How it affects your practice. Manag Care 5 (1996) 30-35
25. Morgan R.O., Virnig B.A., DeVito C.A., and Persily N.A. The Medicare-HMO revolving door-the healthy go in and the sick go out. N Engl J Med 337 (1997) 169-175